Patents
US 12653808 B2: Compounds for treating multiple myeloma
- Granted
- 2026-06-16
- Filed
- 2019-12-18 application 17414806
- Type
- Utility · 17 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The invention relates to tinostamustine for use in the treatment of multiple myeloma. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.
Source: PTBLXML, file of 2026-06-16 (ipgb20260616.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Purdue Pharma L.P. 482 patents | US company or organization | Stamford, CT | PURDUE PHARMA L.P. State business registration EXACT high confidence: identical full name and state | PTBLXML, file of 2026-06-16 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Katarina Hilgier | Zurich, CH | 2 | PTBLXML, file of 2026-06-16 | |
| Francisco Ibanez Lopez | Alicante, ES | 2 | PTBLXML, file of 2026-06-16 | |
| Thomas Jorg Mehrling | Riehen, CH | 25 | PTBLXML, file of 2026-06-16 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/4184 | PTBLXML, file of 2026-06-16 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P7/00 | PTBLXML, file of 2026-06-16 |
| G16H | Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data | G16H20/10 | PTBLXML, file of 2026-06-16 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2026-05-27 | Assignment Assignment of assignor's interest | PURDUE PHARMA L.P. signed 2026-05-01 | KNOA PHARMA LLC STAMFORD, CT | 75841/367 | PASDL, file of 2026-10-15 |
| 2021-11-04 | Assignment Assignment of assignor's interest | MUNDIPHARMA EDO GMBH signed 2019-12-12 | PURDUE PHARMA L.P. STAMFORD, CT | 58016/641 | PASDL, file of 2026-10-15 |
| 2021-11-04 | Assignment Assignment of assignor's interest | HILGIER, KATARINA signed 2019-11-04 LOPEZ, FRANCISCO IBANEZ signed 2019-10-09 MEHRLING, THOMAS JORG signed 2019-10-10 | MUNDIPHARMA EDO GMBH BASEL | 58014/409 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.